NEW YORK (GenomeWeb News) – Celera and Abbott are collaborating on a project to identify genetic markers for an undisclosed investigational compound under development at Abbott, Celera said today.
The partners plan to determine whether genetic variants Celera has identified can predict how patients may respond to treatment with the drug.
Under the terms of this collaboration, Abbott will pay Celera an undisclosed fee to perform the study. Any companion diagnostic product resulting from the study could be developed by Celera and commercialized through its ongoing alliance with Abbott.
“The results of this study will provide new information on the correlation between genetic markers associated with disease and response to therapy,” said Thomas White, chief scientific officer at Celera, in a statement. “Routinely testing this general concept in early clinical trials may give us new and important insights to personalizing disease management.”